Somatuline Predictive Factors in Acromegaly and NET

Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01840449

Acronym

SOPRANo

Enrollment

156

Registered

2013-04-25

Start date

2012-06-30

Completion date

2017-05-31

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly, Neuroendocrine Tumours

Brief summary

The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Interventions

DRUGSomatuline Autogel® 60, 90 or 120 mg

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Written informed consent (also mandatory in case of retrospective documentation of subject data) * Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG

Exclusion criteria

* The subject has already been included in this study * Participation in an interventional trial

Design outcomes

Primary

Measure	Time frame
Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)	Baseline and 1 year

Secondary

Measure	Time frame
Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)	Baseline and 2 years

Countries

Austria, Germany, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026